Your browser doesn't support javascript.
loading
Prospective Trial of Functional Lung Avoidance Radiation Therapy for Lung Cancer: Quality of Life Report.
Lombardo, Joseph; Castillo, Edward; Castillo, Richard; Miller, Ryan; Jones, Bernard; Miften, Moyed; Kavanagh, Brian; Dicker, Adam; Boyle, Cullen; Leiby, Benjamin; Banks, Joshua; Simone, Nicole L; Movsas, Benjamin; Grills, Inga; Guerrero, Thomas; Rusthoven, Chad G; Vinogradskiy, Yevgeniy.
Affiliation
  • Lombardo J; Thomas Jefferson University, Radiation Oncology, Philadelphia, Pennsylvania.
  • Castillo E; UT Austin, Department of Biomedical Engineering, Austin, Texas.
  • Castillo R; Emory University School of Medicine, Radiation Oncology, Atlanta, Georgia.
  • Miller R; Thomas Jefferson University, Radiation Oncology, Philadelphia, Pennsylvania.
  • Jones B; University of Colorado, Radiation Oncology, Denver, Colorado.
  • Miften M; University of Colorado, Radiation Oncology, Denver, Colorado.
  • Kavanagh B; University of Colorado, Radiation Oncology, Denver, Colorado.
  • Dicker A; Thomas Jefferson University, Radiation Oncology, Philadelphia, Pennsylvania.
  • Boyle C; Thomas Jefferson University, Radiation Oncology, Philadelphia, Pennsylvania.
  • Leiby B; Thomas Jefferson University, Department of Pharmacology, Physiology, and Cancer Biology, Philadelphia, Pennsylvania.
  • Banks J; Thomas Jefferson University, Department of Pharmacology, Physiology, and Cancer Biology, Philadelphia, Pennsylvania.
  • Simone NL; Thomas Jefferson University, Radiation Oncology, Philadelphia, Pennsylvania.
  • Movsas B; Henry Ford Cancer Institute, Radiation Oncology, Detroit, Michigan.
  • Grills I; Beaumont Health, Radiation Oncology, Royal Oak, Michigan.
  • Guerrero T; UC San Diego, Radiation Oncology, San Diego, California.
  • Rusthoven CG; University of Colorado, Radiation Oncology, Denver, Colorado.
  • Vinogradskiy Y; Thomas Jefferson University, Radiation Oncology, Philadelphia, Pennsylvania. Electronic address: Yevgeniy.vinogradskiy@jefferson.edu.
Article in En | MEDLINE | ID: mdl-38614278
ABSTRACT

PURPOSE:

A novel form of lung function imaging has been developed that uses 4-dimensional computed tomography (4DCT) data to generate lung ventilation images (4DCT-ventilation). Functional avoidance uses 4DCT-ventilation to reduce doses to functional lung with the aim of reducing pulmonary side effects. A phase 2, multicenter 4DCT-ventilation functional avoidance clinical trial was completed. The purpose of this work was to quantify changes in patient-reported outcomes (PROs) for patients treated with functional avoidance and determine which metrics are predictive of PRO changes. MATERIALS AND

METHODS:

Patients with locally advanced lung cancer receiving curative-intent radiation therapy were accrued. Each patient had a 4DCT-ventilation image generated using 4DCT data and image processing. PRO instruments included the Functional Assessment of Cancer Therapy-Lung (FACT-L) questionnaire administered pretreatment; at the end of treatment; and at 3, 6, and 12 months posttreatment. Using the FACT-Trial Outcome Index and the FACT-Lung Cancer Subscale results, the percentage of clinically meaningful declines (CMDs) were determined. A linear mixed-effects model was used to determine which patient, clinical, dose, and dose-function metrics were predictive of PRO decline.

RESULTS:

Of the 59 patients who completed baseline PRO surveys. 83% had non-small cell lung cancer, with 75% having stage 3 disease. The median dose was 60 Gy in 30 fractions. CMD FACT-Trial Outcome Index decline was 46.3%, 38.5%, and 26.8%, at 3, 6, and 12 months, respectively. CMD FACT-Lung Cancer Subscale decline was 33.3%, 33.3%, and 29.3%, at 3, 6, and 12 months, respectively. Although an increase in most dose and dose-function parameters was associated with a modest decline in PROs, none of the results were significant (all P > .053).

CONCLUSIONS:

The current work presents an innovative combination of use of functional avoidance and PRO assessment and is the first report of PROs for patients treated with prospective 4DCT-ventilation functional avoidance. Approximately 30% of patients had clinically significant decline in PROs at 12 months posttreatment. The study provides additional data on outcomes with 4DCT-ventilation functional avoidance.

Full text: 1 Collection: 01-internacional Database: MEDLINE Language: En Journal: Int J Radiat Oncol Biol Phys Year: 2024 Document type: Article

Full text: 1 Collection: 01-internacional Database: MEDLINE Language: En Journal: Int J Radiat Oncol Biol Phys Year: 2024 Document type: Article